查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012048

糖尿病护理设备市场：2026年至2032年全球市场预测（按设备类型、技术、给药方法、胰岛素类型、分销管道和最终用户划分）

Diabetes Care Devices Market by Device Type, Technology, Delivery Mode, Insulin Type, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，糖尿病护理设备市场价值将达到 321.8 亿美元，到 2026 年将成长至 363.4 亿美元，到 2032 年将达到 777.2 亿美元，复合年增长率为 13.42%。

主要市场统计数据
基准年 2025 321.8亿美元
预计年份：2026年 363.4亿美元
预测年份 2032 777.2亿美元
复合年增长率 (%) 13.42%

糖尿病护理设备市场正经历一场变革，其驱动力包括技术的快速成熟、护理模式的转变以及患者和保险公司日益增长的期望。感测器精度、演算法控制和无线互通性的进步，重新定义了临床医生和糖尿病患者对设备的需求：持续的洞察、可操作的自动化以及与日常生活和临床工作流程的无缝整合。同时，医疗保健系统越来越关注疗效和价值，推动报销路径和采购决策优先考虑那些已被证实能够改善血糖控制、减少併发症并降低整体医疗成本的设备。

在这些因素的共同作用下，製造商、技术合作伙伴和医疗服务提供者正在不断完善其产品蓝图和商业策略。创新日益以患者为中心，重点在于易用性、减轻设备负担和数据透明度。监管机构正在修订其指导方针，以应对软体主导治疗方法和复杂产品，而供应链和製造方面的考量在商业性可行性方面发挥着至关重要的作用。这些发展预示着一个快速变革的时代即将到来，在这个时代，临床疗效、互联互通性、监管灵活性和营运韧性将决定市场领导地位。

闭合迴路自动化、即时连接、智慧给药方案和分散式护理模式如何改变糖尿病设备的开发和商业化。

在糖尿病照护设备领域，变革正在发生，重塑治疗模式和商业策略。首先，结合持续感测和自动胰岛素输注的闭合迴路系统已从小众研究原型发展成为商业性可行性的治疗方案。因此，临床路径正在调整，纳入演算法决策支援和远端监测，护理模式也从间歇性就诊转向持续性照顾。

评估美国 2025 年的关税措施及其对糖尿病医疗设备筹资策略、价格趋势和製造地的连锁影响。

美国将于2025年开始征收关税，这将对糖尿病护理设备的采购、定价策略以及整个供应链产生一系列累积影响。依赖跨境零件采购的製造商正面临原物料成本飙升的困境，被迫即时调整筹资策略和供应商合约。为应对这项挑战，一些企业加快了近岸外包的步伐，或实现了供应商多元化，以降低风险；而另一些企业则寻求透过合约条款来分担或承担关税相关成本。在企业努力控製成本与维持服务水准之间寻求平衡的过程中，这些营运调整正在影响生产前置作业时间和库存管理。

详细的細項分析揭示了设备类型、感测和给药技术、胰岛素配方、分销管道和最终用户环境如何相互交织，从而塑造产品策略。

对市场细分的详细分析揭示了不同设备系列、技术、给药方式、胰岛素製剂、分销管道和终端用户在成长方向和临床价值方面的差异。从设备类型来看，市场构成涵盖了从全封闭回路型和混合封闭回路型架构的全自动人工胰腺系统到包括连续血糖监测、瞬时血糖监测和血糖自我监测在内的血糖监测设备。注射辅助器具包括输液器、笔针和注射器针头，而胰岛素笔则包括预填充填充一次性胰岛素笔、可重复使用胰岛素笔以及日益精密的智慧胰岛素笔。胰岛素帮浦进一步分为贴片帮浦和管式泵，两者在配戴舒适度和储液容量方面各有优劣。

对美洲、欧洲、中东和非洲以及亚太地区影响商业性成功的法规结构、还款促进因素和实施路径进行区域比较分析。

区域趋势正显着影响着美洲、欧洲、中东和非洲以及亚太地区的监管路径、报销框架和产品推广速度。在美洲，对支付方模式和基于价值的合约的高度重视要求製造商证明其产品具有治疗效果和成本效益。这有利于那些能够显着降低急性事件和住院率的医疗设备，从而加速在拥有完善医保覆盖的患者群体中推广互联繫统。同时，在欧洲、中东和非洲，管理体制和采购惯例日益多样化。一些欧洲市场实行集中核准和国家层级的价格谈判，而其他地区则存在准入不均的情况，这就要求在市场准入和循证策略方面采取差异化策略。

主要糖尿病医疗设备製造商的策略行动和竞争措施主要集中在平台整合、伙伴关係、证据生成和供应弹性方面。

糖尿病医疗设备领域的主要企业正将产品创新与生态系统伙伴关係和资本纪律相结合。关键策略措施包括：拓展平台，提供集感测、给药和分析于一体的端到端解决方案；与胰岛素生产商和数位医疗公司建立垂直合作关係；以及选择性地投资于生产能力，以更好地保障供应连续性。一些企业正专注于发展软体即服务 (SaaS) 模式，将分析和护理管理功能以及设备硬体本身实现盈利；而另一些企业则专注于透过小型化、提升佩戴舒适度和增强用户体验来实现硬体差异化。

医疗器材製造商面临的策略挑战是如何协调临床价值、供应弹性、互通性和区域商业化方法，以实现永续成长。

在技​​术快速发展和支付方审查日益严格的环境下，行业领导企业应采取一系列切实可行的倡议，以确保可持续的竞争优势。首先，他们应使产品设计与支付方和医疗服务提供者重视的可衡量结果保持一致，并将循证实践融入产品生命週期，以缩短报销时间并优先考虑端到端的临床价值。其次，他们应透过结合近岸製造和多层供应商合同，实现价值链多元化，从而降低关税风险和零件供应中断的影响。第三，他们应投资于互通性和开放标准，使医疗设备能够整合到电子健康记录和社区健康管理平台中，从而促进医疗系统采用这些标准。

我们采用严格的混合方法，结合监管、临床和商业性证据以及专家访谈和情境分析，来检验我们的见解和建议的有效性。

本报告采用混合方法整合证据，结合全面的二手资料研究、一手质性研究和检验，以确保其可靠性。二手资料来源包括监管文件、同行评审的临床文献、企业技术揭露和政策公告，这些资料提供了事实背景和监管环境。一手研究包括对临床意见领袖、采购专家和高级商业主管进行结构化访谈，以及与保险公司和糖尿病护理协调员进行有针对性的讨论，以检验商业性和报销趋势。

整合策略挑战，凸显向综合、主导糖尿病护理解决方案的过渡以及规模化所需的营运韧性。

总之，在自动化、互联互通和护理模式转移转变的驱动下，糖尿病护理设备产业正从渐进式改善转向系统级转型。相关人员，将更有利于把握新的机会。同时，透过多元化的供应链、区域製造伙伴关係和积极的关税措施来体现的业务永续营运韧性，已不再是后勤部门的挑战，而是保持竞争力的必要条件。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 糖尿病护理设备市场：依设备类型划分

  • 人工胰臟系统
    • 完全封闭回路型
    • 混合闭合迴路
  • 血糖监测设备
    • 持续血糖监测
    • 瞬时血糖监测
    • 自测血糖
  • 注射辅助器具
    • 注射套装
    • 笔针
    • 针头
  • 胰岛素笔
    • 预填充一次性笔
    • 可重复使用的笔
    • 智慧笔
  • 胰岛素帮浦
    • 贴片帮浦
    • 管式帮浦
  • 胰岛素注射器

第九章 糖尿病护理设备市场：依技术划分

  • 持续血糖监测
    • 即时连续血糖监测
    • 回顾性连续血糖监测
  • 瞬时血糖监测
  • 自测血糖
    • 血糖仪
    • 《采血针》
    • 测量条

第十章 糖尿病照护设备市场：依给药方式划分

  • 持续管理
  • 间歇性给药

第十一章 糖尿病照护设备市场：依胰岛素类型划分

  • 中间类型
  • 长效型
    • 德特米尔
    • 格拉金
  • 超速效型
    • Aspart
    • Glulisine
    • Lispro
  • 快速起效
  • 超长效

第十二章 糖尿病护理设备市场：依通路划分

  • 线上管道
  • 离线
    • 零售药房
    • 医院药房

第十三章 糖尿病护理设备市场：依最终用户划分

  • 诊断中心
  • 居家照护
  • 医院和诊所
    • 糖尿病专科诊所
    • 一般诊所

第十四章 糖尿病照护设备市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 糖尿病照护设备市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 糖尿病照护设备市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国：糖尿病照护设备市场

第十八章 中国：糖尿病护理设备市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Acon Laboratories Inc.
  • ARKray Inc.
  • Ascensia Diabetes Care Holdings AG
  • B. Braun Melsungen AG
  • Becton Dickinson and Company BD
  • Bionime Corporation
  • Dexcom Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Insulet Corporation
  • LifeScan Inc.
  • Medtronic plc
  • Menarini Diagnostics
  • MicroTech Medical Inc.
  • Nipro Corporation
  • Novo Nordisk A/S
  • Sanofi
  • Senseonics Holdings Inc.
  • Sinocare
  • Tandem Diabetes Care Inc.
  • Terumo Corporation
  • Trividia Health
  • Valeritas Holdings Inc.
  • Ypsomed Holding AG
Product Code: MRR-43539E5D2EA5

The Diabetes Care Devices Market was valued at USD 32.18 billion in 2025 and is projected to grow to USD 36.34 billion in 2026, with a CAGR of 13.42%, reaching USD 77.72 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 32.18 billion
Estimated Year [2026] USD 36.34 billion
Forecast Year [2032] USD 77.72 billion
CAGR (%) 13.42%

The diabetes care devices landscape is at a pivotal moment, driven by rapid technological maturation, shifting care delivery models, and intensifying expectations from patients and payers alike. Advances in sensor accuracy, algorithmic control, and wireless interoperability have recalibrated what clinicians and people living with diabetes expect from devices: continuous insights, actionable automation, and seamless integration into daily life and clinical workflows. At the same time, healthcare systems are emphasizing outcomes and value, prompting reimbursement pathways and procurement decisions to prioritize devices that demonstrably improve glycemic control, reduce complications, and lower total cost of care.

As these forces converge, manufacturers, technology partners, and healthcare providers are refining product roadmaps and commercial strategies. Innovation is increasingly patient-centric, focusing on ease of use, reduced device burden, and data transparency. Regulatory authorities are evolving guidance to accommodate software driven therapeutics and combination products, while supply chain and manufacturing considerations now play an outsized role in commercial viability. Taken together, these dynamics set the stage for a period of accelerated disruption where clinical efficacy, connectivity, regulatory agility, and operational resilience will determine market leadership.

How closed-loop automation, real-time connectivity, smart delivery options, and decentralized care models are reshaping diabetes device development and commercialization

The landscape of diabetes care devices has undergone transformative shifts that are redefining therapeutic paradigms and commercial playbooks. First, closed-loop systems that combine continuous sensing with automated insulin delivery have transitioned from niche research prototypes to commercially viable therapeutic options. As a result, clinical pathways are adapting to incorporate algorithmic decision support and remote monitoring, moving care from episodic encounters to continuous care relationships.

Concurrently, the proliferation of connected devices and cloud platforms has created richer longitudinal datasets that enable more personalized therapy adjustments and population-level analytics. This data availability is catalyzing partnerships between device manufacturers, software developers, and payers, fostering an ecosystem where interoperability and secure data exchange are commercial differentiators. In parallel, the rise of smart pens and advanced injection aids has broadened the options for insulin delivery, offering alternatives that can bridge the gap between lifestyle convenience and clinical efficacy. Finally, the industry is witnessing a shift toward decentralization of care: telehealth, home diagnostics, and remote titration are reducing the reliance on centralized clinics, and in doing so, reshaping distribution strategies, educational outreach, and customer support models.

Assessment of the 2025 United States tariff measures and their cascading effects on sourcing strategies, pricing dynamics, and manufacturing footprints across diabetes devices

The imposition of tariffs in the United States during 2025 has introduced a set of cumulative effects that ripple across procurement, pricing strategies, and supply chains for diabetes care devices. Manufacturers that rely on cross-border component sourcing have encountered escalated input costs, prompting immediate reassessment of sourcing strategies and supplier contracts. In response, some organizations accelerated nearshoring initiatives or diversified supplier bases to mitigate exposure, while others sought contractual clauses to share or absorb tariff related costs. These operational adjustments have implications for production lead times and inventory management as firms balance cost containment with service level commitments.

From a commercial perspective, tariffs have created pressure on device pricing and reimbursement negotiations. Payers and purchasing groups have become more vigilant about unit costs and lifecycle expenditures, which in turn influences formulary decisions and tender outcomes for hospitals and clinics. Some manufacturers opted to absorb tariff impacts temporarily to preserve market access, while others introduced price adjustments tied to specific product lines. At the same time, the tariff environment has incentivized investment in domestic manufacturing capabilities and strategic partnerships with local contract manufacturers, reflecting a longer-term pivot to reduce trade risk. Ultimately, the tariff episode accelerated structural shifts in sourcing, manufacturing footprint decisions, and commercial terms that will influence competitive dynamics beyond the immediate fiscal cycle.

Deep segmentation analysis revealing how device type, sensing and delivery technologies, insulin formulations, channels, and end user settings intersect to shape product strategies

A nuanced view of segmentation reveals divergent growth vectors and differentiated clinical value across device families, technologies, delivery modes, insulin formulations, channels, and end users. When examined by device type, the market composition ranges from fully automated artificial pancreas systems comprising full closed loop and hybrid closed loop architectures to glucose monitoring devices that cover continuous glucose monitoring, flash glucose monitoring, and self-monitoring blood glucose. The injection aids spectrum includes infusion sets, pen needles, and syringe needles, while insulin pens span prefilled disposable pens, reusable pens, and increasingly sophisticated smart pens. Insulin pumps are further categorized into patch pumps and tubed pumps, each offering distinct tradeoffs in wearability and reservoir capacity.

Looking through a technology lens, continuous glucose monitoring itself bifurcates into real-time continuous glucose monitoring and retrospective continuous glucose monitoring, and remains distinct from flash glucose monitoring and self-monitoring blood glucose approaches; the latter includes glucose meters, lancets, and test strips. Delivery mode segmentation divides offerings into continuous delivery and intermittent delivery, which align to different clinical profiles and patient preferences. Insulin types span intermediate acting through ultra long acting formulations, with commonly used long acting analogues such as detemir and glargine and rapid acting analogues including aspart, glulisine, and lispro shaping device compatibility and dosing algorithms. Distribution channel dynamics encompass direct sales, hospital pharmacies, online channels, and retail pharmacies, with retail channels further split between chain and independent pharmacies. Finally, end user segmentation covers diagnostic centers, home care settings, and hospitals and clinics, where the latter includes specialized diabetes clinics as well as general clinics.

Taken together, these segmentation layers intersect to inform product design priorities, clinical positioning, and go-to-market approaches. For example, smart pens and continuous technologies align strongly with home care adoption and online distribution, while hybrid and full closed loop systems require integrated support from hospitals, diabetes clinics, and specialized diagnostic services during early adoption phases. Manufacturers should therefore map technology choices to distribution and end user pathways to optimize clinical impact and commercial uptake.

Comparative regional intelligence on regulatory frameworks, reimbursement drivers, and adoption pathways across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine commercial success

Regional dynamics materially influence regulatory pathways, reimbursement frameworks, and adoption tempos across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, payer models and a strong emphasis on value-based contracting have pushed manufacturers to demonstrate outcomes and cost offsets. This has favored devices that enable measurable reductions in acute events and hospital utilization, and has accelerated uptake of connected systems in populations with established coverage pathways. Conversely, Europe, Middle East & Africa presents a mosaic of regulatory regimes and procurement practices; centralized approvals and national pricing negotiations in some European markets contrast with heterogeneous access in other jurisdictions, requiring differentiated market entry and evidence generation strategies.

Asia-Pacific markets exhibit diverse demand drivers, where high population density and rising prevalence create scale opportunities, while variable reimbursement and income levels necessitate tiered product offerings and channel innovation. In several markets, local manufacturing partnerships and licensing arrangements have been critical to navigating import duties and securing preferred provider status. Across regions, technology adoption curves differ: while some countries rapidly embrace continuous monitoring and closed-loop approaches, others prioritize cost-effective intermittent delivery solutions and robust supply chain resilience. Manufacturers should therefore calibrate clinical evidence dossiers, pricing approaches, and partnership models in accordance with regional payer expectations and regulatory realities to maximize adoption and reimbursement success.

Strategic behaviors and competitive moves among leading diabetes device manufacturers focused on platform integration, partnerships, evidence generation, and supply resilience

Leading companies in the diabetes devices space are aligning product innovation with ecosystem partnerships and capital discipline. Key strategic behaviors include platform expansion to deliver end-to-end solutions that combine sensing, delivery, and analytics; vertical partnerships with insulin manufacturers and digital health firms; and selective investments in manufacturing capabilities to enhance control over supply continuity. Some organizations emphasize software as a service models, monetizing analytics and care management features alongside device hardware, while others double down on hardware differentiation through miniaturization, improved wearability, and enhanced user experience.

Competitive dynamics are also shaped by M&A, licensing, and co-development agreements that accelerate time to market for complex combination products. Companies that succeed tend to integrate clinical evidence generation into commercialization plans early, aligning randomized and real-world evidence to payer decision needs. Additionally, leaders invest in customer education, professional training, and post-market surveillance to reinforce clinical trust and reduce device attrition. Finally, a growing number of firms are committing to sustainability in manufacturing and packaging as a reputational and cost consideration, recognizing that procurement teams increasingly factor environmental impact into purchasing decisions.

Actionable strategic imperatives for device manufacturers to align clinical value, supply resilience, interoperability, and regional commercialization approaches for sustained growth

Industry leaders should pursue a set of pragmatic actions to secure durable advantage in a landscape defined by technological acceleration and payer scrutiny. First, prioritize end-to-end clinical value by aligning product design with measurable outcomes that matter to payers and providers, and embed evidence generation in product lifecycles to shorten reimbursement timelines. Second, diversify supply chains by combining nearshore manufacturing options with multi-tier supplier agreements to mitigate tariff exposure and component disruptions. Third, invest in interoperability and open standards to ensure devices can integrate into electronic health records and population health platforms, thereby increasing adoption by health systems.

Fourth, develop tiered commercial offerings that address distinct regional affordability profiles, pairing premium, fully integrated systems with simplified, cost-effective alternatives for resource constrained markets. Fifth, cultivate strategic partnerships with insulin producers, digital therapeutics firms, and telehealth providers to create bundled solutions that align incentives across stakeholders. Sixth, accelerate post-market programs that support clinician training and patient onboarding, reducing friction in adoption and improving retention. Together, these actions will enable manufacturers to navigate regulatory complexities, respond to evolving clinical expectations, and capture long-term share in an increasingly outcomes-oriented market.

Rigorous mixed methods research combining regulatory, clinical, and commercial evidence with expert interviews and scenario analysis to validate insights and recommendations

This report synthesizes evidence using a mixed-methods approach that combines comprehensive secondary research with primary qualitative inquiry and triangulation to ensure robustness. Secondary inputs include regulatory filings, peer-reviewed clinical literature, company technical disclosures, and policy announcements that establish the factual backdrop and regulatory context. Primary research incorporated structured interviews with clinical opinion leaders, procurement specialists, and senior commercial executives, along with targeted discussions with payers and diabetes care coordinators to validate commercial and reimbursement dynamics.

Analytical processes included cross-validation of qualitative insights against published clinical outcomes and regulatory guidance, scenario analysis to stress test the implications of tariffs and supply disruptions, and thematic coding of interview outputs to surface recurring adoption barriers and enablers. Quality assurance steps encompassed independent review by subject matter experts and reconciliation of divergent viewpoints to create balanced conclusions. Ethical research conduct and data privacy protocols were maintained throughout, ensuring that proprietary commercial information was handled under confidentiality and that synthesized findings reflect consensus where possible rather than single-source assertions.

Synthesis of strategic imperatives underscoring the transition to integrated, evidence-driven diabetes care solutions and the operational resilience required for scale

In conclusion, the diabetes care devices sector is transitioning from incremental improvement to systems-level transformation, driven by automation, connectivity, and shifting care paradigms. Stakeholders who move beyond product centric thinking to embrace integrated solutions that deliver measurable clinical and economic value will be best positioned to capture emerging opportunities. At the same time, operational resilience-manifested through diversified supply chains, regional manufacturing partnerships, and proactive tariff mitigation-has become a competitive necessity rather than a back-office concern.

Looking ahead, success will hinge on the ability to translate rich device-generated data into actionable clinical workflows, to secure payer alignment through strong evidence packages, and to offer flexible commercial models adapted to regional contexts. For manufacturers, investors, and healthcare systems alike, the mandate is clear: pursue innovations that make diabetes care simpler, safer, and more accessible, while building the commercial and operational muscle to deliver those innovations at scale.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Diabetes Care Devices Market, by Device Type

  • 8.1. Artificial Pancreas Systems
    • 8.1.1. Full Closed Loop
    • 8.1.2. Hybrid Closed Loop
  • 8.2. Glucose Monitoring Devices
    • 8.2.1. Continuous Glucose Monitoring
    • 8.2.2. Flash Glucose Monitoring
    • 8.2.3. Self Monitoring Blood Glucose
  • 8.3. Injection Aids
    • 8.3.1. Infusion Sets
    • 8.3.2. Pen Needles
    • 8.3.3. Syringe Needles
  • 8.4. Insulin Pens
    • 8.4.1. Prefilled Disposable Pens
    • 8.4.2. Reusable Pens
    • 8.4.3. Smart Pens
  • 8.5. Insulin Pumps
    • 8.5.1. Patch Pumps
    • 8.5.2. Tubed Pumps
  • 8.6. Insulin Syringes

9. Diabetes Care Devices Market, by Technology

  • 9.1. Continuous Glucose Monitoring
    • 9.1.1. Real Time Continuous Glucose Monitoring
    • 9.1.2. Retrospective Continuous Glucose Monitoring
  • 9.2. Flash Glucose Monitoring
  • 9.3. Self Monitoring Blood Glucose
    • 9.3.1. Glucose Meters
    • 9.3.2. Lancets
    • 9.3.3. Test Strips

10. Diabetes Care Devices Market, by Delivery Mode

  • 10.1. Continuous Delivery
  • 10.2. Intermittent Delivery

11. Diabetes Care Devices Market, by Insulin Type

  • 11.1. Intermediate Acting
  • 11.2. Long Acting
    • 11.2.1. Detemir
    • 11.2.2. Glargine
  • 11.3. Rapid Acting
    • 11.3.1. Aspart
    • 11.3.2. Glulisine
    • 11.3.3. Lispro
  • 11.4. Short Acting
  • 11.5. Ultra Long Acting

12. Diabetes Care Devices Market, by Distribution Channel

  • 12.1. Online Channels
  • 12.2. Offline
    • 12.2.1. Retail Pharmacies
    • 12.2.2. Hospital Pharmacies

13. Diabetes Care Devices Market, by End User

  • 13.1. Diagnostic Centers
  • 13.2. Home Care
  • 13.3. Hospitals And Clinics
    • 13.3.1. Diabetes Clinics
    • 13.3.2. General Clinics

14. Diabetes Care Devices Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Diabetes Care Devices Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Diabetes Care Devices Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Diabetes Care Devices Market

18. China Diabetes Care Devices Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Acon Laboratories Inc.
  • 19.7. ARKray Inc.
  • 19.8. Ascensia Diabetes Care Holdings AG
  • 19.9. B. Braun Melsungen AG
  • 19.10. Becton Dickinson and Company BD
  • 19.11. Bionime Corporation
  • 19.12. Dexcom Inc.
  • 19.13. Eli Lilly and Company
  • 19.14. F. Hoffmann-La Roche Ltd.
  • 19.15. Insulet Corporation
  • 19.16. LifeScan Inc.
  • 19.17. Medtronic plc
  • 19.18. Menarini Diagnostics
  • 19.19. MicroTech Medical Inc.
  • 19.20. Nipro Corporation
  • 19.21. Novo Nordisk A/S
  • 19.22. Sanofi
  • 19.23. Senseonics Holdings Inc.
  • 19.24. Sinocare
  • 19.25. Tandem Diabetes Care Inc.
  • 19.26. Terumo Corporation
  • 19.27. Trividia Health
  • 19.28. Valeritas Holdings Inc.
  • 19.29. Ypsomed Holding AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIABETES CARE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIABETES CARE DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DIABETES CARE DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES DIABETES CARE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA DIABETES CARE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIABETES CARE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FULL CLOSED LOOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FULL CLOSED LOOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FULL CLOSED LOOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HYBRID CLOSED LOOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HYBRID CLOSED LOOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HYBRID CLOSED LOOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INFUSION SETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INFUSION SETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INFUSION SETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PEN NEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PEN NEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PEN NEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SYRINGE NEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SYRINGE NEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SYRINGE NEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PREFILLED DISPOSABLE PENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PREFILLED DISPOSABLE PENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PREFILLED DISPOSABLE PENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REUSABLE PENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REUSABLE PENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REUSABLE PENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SMART PENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SMART PENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SMART PENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PATCH PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PATCH PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PATCH PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TUBED PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TUBED PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TUBED PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REAL TIME CONTINUOUS GLUCOSE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REAL TIME CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REAL TIME CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETROSPECTIVE CONTINUOUS GLUCOSE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETROSPECTIVE CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETROSPECTIVE CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE METERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE METERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE METERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LANCETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LANCETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LANCETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TEST STRIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TEST STRIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMITTENT DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMITTENT DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMITTENT DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMEDIATE ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMEDIATE ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMEDIATE ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DETEMIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DETEMIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DETEMIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLARGINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLARGINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLARGINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ASPART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ASPART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ASPART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLULISINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLULISINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLULISINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LISPRO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LISPRO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LISPRO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SHORT ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SHORT ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SHORT ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ULTRA LONG ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ULTRA LONG ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ULTRA LONG ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIABETES CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIABETES CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIABETES CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2018-2032 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2018-2032 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2018-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2018-2032 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 308. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 309. ASEAN DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 310. ASEAN DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD